Tarsus Pharmaceuticals (TARS) Net Cash Flow Growth (1y) (2020 - 2026)
Tarsus Pharmaceuticals (TARS) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 53.46% |
| 10 | Tarsus Pharmaceuticals | 2.61 Bn | 2.51 Bn | 152.66 Mn | -201.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -201.29% |
| Dec 31, 2025 | 189.96% |
| Sep 30, 2025 | 429.09% |
| Jun 30, 2025 | -527.59% |
| Mar 31, 2025 | 359.17% |
| Dec 31, 2024 | -4,469.80% |
| Sep 30, 2024 | -104.07% |
| Jun 30, 2024 | -130.93% |
| Mar 31, 2024 | -451.69% |
| Dec 31, 2023 | 98.24% |
| Sep 30, 2023 | 258.02% |
| Jun 30, 2023 | -42.04% |
| Mar 31, 2023 | -253.97% |
| Dec 31, 2022 | -684.58% |
| Sep 30, 2022 | -1,173.79% |
| Jun 30, 2022 | 242.58% |
| Mar 31, 2022 | 130.78% |
| Dec 31, 2021 | -115.24% |
| Sep 30, 2021 | -78.71% |
| Jun 30, 2021 | 844.60% |